Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0017 USD
Change Today +0.0002 / 13.33%
Volume 15.0K
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

calypte biomedical corp (CBMC) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $0.02
52 Week Low
03/16/15 - $0.0001
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

calypte biomedical corp (CBMC) Related Businessweek News

No Related Businessweek News Found

calypte biomedical corp (CBMC) Details

Calypte Biomedical Corporation develops, manufactures, and distributes in vitro diagnostic tests primarily for the diagnosis of human immunodeficiency virus (HIV) infection. The company focuses on the commercialization of HIV-1/2 rapid test products for the rapid detection of antibodies to HIV-1 and HIV Type 2 in oral fluid using a lateral flow dipstick design. Its products also comprise Aware HIV-1/2 OMT test to address the drawbacks of blood testing; and Aware HIV-1/2 Oral OTC test, which is an over-the-counter version of oral fluid rapid test. In addition, the company provides Aware BED HIV-1 Incidence Test that is used to estimate the rate of new HIV infections in a population by determining proportion of a population of HIV infected people were infected within approximately the past six months, and could be used by public health agencies to identify those regions and the populations within them where HIV transmission is occurring most recently. Further, it offers Aware Messenger, an oral fluid collection device, which is intended for the collection, stabilization, and transportation of an oral fluid specimen to be used for the detection of specific antibodies or other substances. Additionally, it intends to provide Aware 2 line, a testing solution with a cassette-housed strip. The company sells its products through local distributors in the United States; and products primarily in Africa and the Middle East. Calypte Biomedical Corporation was founded in 1988 and is headquartered in Portland, Oregon.

3 Employees
Last Reported Date: 06/24/14
Founded in 1988

calypte biomedical corp (CBMC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

calypte biomedical corp (CBMC) Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Calypte Biomedical Corporation For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Calypte Biomedical Corp. Auditor Raises 'Going Concern' Doubt

Calypte Biomedical Corp. filed its 10-K on Jun 24, 2014 for the period ending Dec 31, 2012. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Calypte Biomedical Corporation Amends Restated Certificate of Incorporation

On March 14, 2014, the Calypte Biomedical Corporation amended its restated certificate of incorporation to increase the number of authorized shares of common stock from 800,000,000 to 2,400,000,000 and decrease the par value of the common stock to $0.005.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBMC:US $0.00 USD +0.0002

CBMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBMC.
View Industry Companies

Industry Analysis


Industry Average

Valuation CBMC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALYPTE BIOMEDICAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at